MedTrace Logo

Phase 2 Randomized Study of PG-102 vs Placebo and Semaglutide in Type 2 Diabetes Mellitus

NCT07187856 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2025-09-23

No results posted yet for this study

Summary

Phase 2 Randomized Study of PG-102 vs Placebo and Semaglutide in Type 2 Diabetes Mellitus

Conditions

  • Type 2 Diabetes Mellitus (T2DM)

Interventions

DRUG

PG-102

PG-102 is administered subcutaneously once weekly with a titration regimen.

DRUG

Placebo

Placebo is administered subcutaneously once weekly.

DRUG

Semaglutide

Open-label semaglutide is administered subcutaneously once weekly with titration regimen.

Sponsors & Collaborators

  • ProGen. Co., Ltd.

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-31
Primary Completion
2026-09-30
Completion
2026-12-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07187856 on ClinicalTrials.gov